GlassScriptPhysician profile
Bassam Hajjar
NPI 1316024946
$5,417.78
in general payments reported to CMS, 2019-2025
31 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $225 · 2021: $616 · 2022: $715 · 2023: $1,027 · 2024: $1,041 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $599.04 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $543.53 | 2019-2025 | Xifaxan, Plenvu |
| Amgen INC. | $457.88 | 2023-2025 | Repatha, Repatha |
| Aimmune Therapeutics, INC. | $330.60 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $310.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $297.36 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $241.29 | 2019-2024 | |
| Pfizer INC. | $214.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.86 | 2019-2024 | Entyvio |
| Novo Nordisk INC | $157.89 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $151.09 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $143.32 | 2025 | Korlym |
| Medtronic Vascular, INC. | $137.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $126.39 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $110.02 | 2020-2024 | Ocaliva |
| Ardelyx, INC. | $105.78 | 2022-2023 | Ibsrela |
| Braintree Laboratories, INC. | $49.87 | 2021-2022 | |
| Allergan, INC. | $40.46 | 2019 | |
| Dexcom, INC. | $38.76 | 2021 | |
| Janssen Biotech, INC. | $37.50 | 2022-2025 | Stelara, Simponi Aria, Tremfya |
| Phathom Pharmaceuticals, INC. | $31.93 | 2024 | Voquezna |
| Evoke Pharma, INC. | $28.61 | 2021 | |
| Glaxosmithkline, LLC. | $28.40 | 2021-2022 | |
| Redhill Biopharma INC. | $27.70 | 2021-2022 | |
| Biogen, INC. | $21.46 | 2022 | |
| Celgene Corporation | $15.65 | 2023 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $15.15 | 2023 | Dat Closure Device |
| Nestle Healthcare Nutrition INC. | $15.02 | 2022 | |
| Eisai INC. | $14.86 | 2021 | |
| Shire North American Group INC | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassam Hajjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.